Log In
Print
BCIQ
Print
Print this Print this
 

Anti-IL-20 (NN8226)

Also known as: formerly Anti-IL20

  Manage Alerts
Collapse Summary General Information
Company Novo Nordisk A/S
DescriptionRecombinant human mAb neutralizing IL-20
Molecular Target Interleukin-20 (IL-20)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat rheumatoid arthritis (RA)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today